Increasingly, moderate-to-severe psoriasis represents an increasingly lucrative market for targeted systemic treatments. Although adult psoriasis and pediatric psoriasis are similar, there are more adult psoriasis clinical variations than pediatric psoriasis, and adult psoriasis treatments far exceed that of pediatric psoriasis. TNF-alpha inhibitors, Otezla (Celgene), and the IL-12/23 inhibitor Stelara (Janssen) continue to dominate targeted therapy patient share. However, the more recent arrival of IL-17 inhibitors has shaken up the market; notably, the first-in-class Cosentyx (Novartis) as well as the second-in-class Taltz (Eli Lilly) are gaining patient share in earlier lines of therapy.
· What patient share do key therapies and brands garner by line of therapy in newly diagnosed psoriasis patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed psoriasis patients?
· How have non-TNF-alpha inhibitor
· What proportion of psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
· What percentage of psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
· What are the product-level compliance and persistency rates among drug-treated patients with psoriasis?